Goldline Pharmaceutical SME IPO GMP History | Listing Price ₹59.75 & Kostak Rate
Goldline Pharmaceutical SME IPO has been listed on May 19, 2026 at a listing price of ₹59.75, against the issue price of ₹43 — a gain of ₹16.75 (+38.95%). The GMP peaked at ₹25 on 13 May 2026 and reached a low of ₹8 on 9 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Goldline Pharmaceutical SME IPO raised ₹12 Cr. through its IPO at a price band of ₹41 to ₹43 per share, with a lot size of 3000 shares. The IPO was open for subscription from 12 May 2026 to 14 May 2026.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 3 Sep, 2:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 18 May 2026 | ₹ 15 | ▼ | 35% | ₹ 0 | ₹ 0 |
| 17 May 2026 | ₹ 20 | ▲ | 47% | ₹ 0 | ₹ 0 |
| 15 May 2026 | ₹ 18 | ▲ | 42% | ₹ 0 | ₹ 0 |
| 14 May 2026 | ₹ 15 | ▼ | 35% | ₹ 0 | ₹ 0 |
| 13 May 2026 | ₹ 25 | ▲ | 58% | ₹ 0 | ₹ 0 |
| 12 May 2026 | ₹ 18 | ▲ | 42% | ₹ 0 | ₹ 0 |
| 11 May 2026 | ₹ 17 | ▲ | 40% | ₹ 0 | ₹ 0 |
| 10 May 2026 | ₹ 15 | ▲ | 35% | ₹ 0 | ₹ 0 |
| 09 May 2026 | ₹ 8 | — | 19% | ₹ 0 | ₹ 0 |
| 08 May 2026 | ₹ 8 | — | 19% | ₹ 0 | ₹ 0 |
Goldline Pharmaceutical SME IPO dates
Key dates from opening to listing. Today is 20 September.
- Open 12 May 2026
- Close 14 May 2026
- Allotment 15 May 2026
- Refund/credit 18 May 2026
- Listing 19 May 2026
Goldline Pharmaceutical SME IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹43 |
|---|---|
| GMP-based estimate (pre-listing) | ₹58 (+34.9%) |
| Listing gain / loss | +₹16.75 per share |
| Listing date | 19 May, 2026 |
| Actual listing price | ₹59.75 (+38.95%) |
Is Goldline Pharmaceutical SME IPO GMP reliable?
Grey market premium for Goldline Pharmaceutical SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Goldline Pharmaceutical SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Goldline Pharmaceutical SME IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Goldline Pharmaceutical SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Goldline Pharmaceutical SME IPO
Goldline Pharmaceutical Limited was established in 2005 and is engaged in the marketing and distribution of pharmaceutical formulations across India. The company has built its presence through a wide portfolio of healthcare products catering to multiple therapeutic segments. Over the years, Goldline has expanded its distribution network and strengthened relationships with doctors, distributors, and healthcare professionals. The company is promoted by experienced industry professionals who focus on expanding the brand presence and improving market reach in the domestic pharmaceutical sector.
The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.
Frequently asked
What is the GMP of Goldline Pharmaceutical SME IPO?
The current Grey Market Premium (GMP) of Goldline Pharmaceutical SME IPO is ₹ 15.
What is the Kostak Price of Goldline Pharmaceutical SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Goldline Pharmaceutical SME IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What is the Subject to Sauda Price of Goldline Pharmaceutical SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What was the actual listing price of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO listed on May 19, 2026 at ₹59.75, against the issue price of ₹43 — a gain of +38.95%.
How did the GMP of Goldline Pharmaceutical SME IPO trend before listing?
The GMP of Goldline Pharmaceutical SME IPO was falling in its final days before listing. The GMP peaked at ₹25 on 13 May 2026. View the day-wise table above for the complete GMP history.
Explore Goldline Pharmaceutical SME IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
